Responses
Regular and Young Investigator Award Abstracts
Novel Single-Agent Immunotherapies
1334 OBT698: a promising novel agonistic antibody for immuno-oncology and its potential as a cancer therapy for solid tumors
Compose a Response to This Article
Other responses
No responses have been published for this article.
